Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of “Buy” from Analysts

Bioventus Inc. (NASDAQ:BVS) has been given an average rating of “Buy” by the five analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.00.

A number of equities research analysts have commented on the company. Craig Hallum raised their price objective on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, March 6th. CJS Securities assumed coverage on Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price on the stock. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. Finally, Barrington Research reissued an “outperform” rating and issued a $14.00 price target on shares of Bioventus in a research report on Friday.

Bioventus Price Performance

BVS stock opened at $9.28 on Tuesday. The stock has a market capitalization of $775.25 million, a PE ratio of 22.63, a price-to-earnings-growth ratio of 1.18 and a beta of 0.72. The company’s 50-day moving average is $9.67 and its 200-day moving average is $8.50. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13. Bioventus has a 1 year low of $5.81 and a 1 year high of $11.25.

Bioventus (NASDAQ:BVS) last issued its earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The business had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities research analysts expect that Bioventus will post 0.79 EPS for the current fiscal year.

Insider Buying and Selling at Bioventus

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares in the company, valued at $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 33.00% of the company’s stock.

Institutional Investors Weigh In On Bioventus

A number of institutional investors and hedge funds have recently made changes to their positions in BVS. Caitong International Asset Management Co. Ltd lifted its position in Bioventus by 17,156.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after acquiring an additional 5,490 shares in the last quarter. Covestor Ltd increased its holdings in Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after purchasing an additional 2,176 shares in the last quarter. Prelude Capital Management LLC purchased a new stake in shares of Bioventus in the third quarter worth approximately $74,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Bioventus in the third quarter worth approximately $78,000. Finally, SG Americas Securities LLC bought a new position in shares of Bioventus in the fourth quarter valued at approximately $80,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.